The South Korean pharmaceutical company will produce 150 million doses of the Russian “Satellite V” vaccine
November 13, local time, the Russian Sovereign Wealth Fund (RDIF) stated that it had signed an agreement with South Korean biotechnology company GL Rapha to produce 150 million doses of “Satellite V” vaccines in South Korea each year.
Russian Sputnik News Agency reported on the 13th that the Russian sovereign wealth fund stated in a statement: “The two parties plan to start producing the’Satellite V’vaccine in December 2020 and launch it in January 2021. According to the plan, RDIF and GL Rapha More than 150 million doses of vaccines produced in Korea will be provided to the world every year.
40,000 volunteers participated in the third phase of the “Satellite V” clinical test. The first interim analysis showed that the effectiveness of the “Satellite V” vaccine was 92%.
RDIF CEO Kirill Dmitriev said: “Satellite V is built on a safe and effective human adenovirus vector platform. As the pandemic is far from over, more and more The country recognizes the potential of the human adenovirus vector platform and plans to include it in its national vaccine portfolio.” RDIF said at a press conference that it has received orders from more than 50 countries, and the total demand for Coronavirus vaccines exceeds 1.2 billion doses, so it is considering increasing its foreign productivity.
“Satellite V” is the world’s first Coronavirus vaccine registered in Russia on August 11. The vaccine was developed by the National Research Center for Epidemiology and Microbiology of Gamaliel, and is currently undergoing phase III clinical trials.
The interim research data will be published in leading international peer-reviewed medical journals by the National Research Center for Epidemiology and Microbiology of Gamallea. According to the news released by the research and development party of “Satellite V” on Twitter on November 11, the observation of the test volunteers will continue for six months, after which the complete clinical trial report will be released after the completion of the third phase of the clinical trial.
